Published in J Clin Med on May 09, 2014
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med (2001) 9.99
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
The stem-cell niche as an entity of action. Nature (2006) 7.73
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol (2011) 5.63
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
Self-renewal and solid tumor stem cells. Oncogene (2004) 4.60
CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res (2004) 4.53
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene (2008) 4.53
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
Subtypes of breast cancer show preferential site of relapse. Cancer Res (2008) 4.38
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet (2013) 3.90
Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res (2007) 3.49
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 3.38
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med (2008) 3.05
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther (2002) 2.83
Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res (2010) 2.77
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol (2010) 2.74
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol (2010) 2.64
The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer (2011) 2.55
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol (2012) 2.16
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
Breast cancer stem cells: a new target for therapy. Oncology (Williston Park) (2011) 2.09
Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res (2008) 2.06
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer (2010) 1.91
Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat (2009) 1.69
Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst (2012) 1.69
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 1.65
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol (2008) 1.59
Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer (2003) 1.58
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56
Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst (2007) 1.56
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One (2011) 1.44
Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res (2011) 1.43
Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.42
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer (2011) 1.37
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer (2011) 1.36
Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev (2011) 1.34
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res (2008) 1.30
NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res (2009) 1.27
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res (2010) 1.18
Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer (2010) 1.16
The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol (2013) 1.16
Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res (2011) 1.16
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer (2005) 1.16
HER2 and breast cancer stem cells: more than meets the eye. Cancer Res (2013) 1.14
Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Eur J Cancer (2010) 1.11
Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients. Ann Oncol (2012) 1.11
A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. Clin Cancer Res (2011) 1.08
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res (2009) 1.06
Meta-analysis of clodronate and breast cancer survival. Br J Cancer (2007) 1.06
Breast cancer dormancy can be maintained by small numbers of micrometastases. Cancer Res (2010) 1.06
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer (2003) 1.05
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol (2011) 1.03
CD8+ T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res (2011) 1.00
Stem cells in breast tumours: are they ready for the clinic? Eur J Cancer (2012) 1.00
Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer--a randomized biomarker pilot study. Clin Cancer Res (2013) 0.99
SRC inhibitors in metastatic bone disease. Clin Cancer Res (2006) 0.99
Src kinases catalytic activity regulates proliferation, migration and invasiveness of MDA-MB-231 breast cancer cells. Cell Signal (2012) 0.98
Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol (2011) 0.79